News

The Gazette with CEA Technologies

Saturday, March 31, 2012

Q&A with Marcus Boggs: Practicing open-book management

THE GAZETTE
Marcus Boggs has shared both financial results and profits with employees of CEA Technologies Inc. since he started the privately held contract medical device engineering and manufacturing company in Colorado Springs in 1988. 

Ariel Appoints Dr. Catherine Sohn to BoD

Friday, March 30, 2012

Broomfield, CO, March 30, 2012 – Ariel Pharmaceuticals, Inc., a private, development-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products for major unmet medical needs, announced today that Catherine Angell Sohn, Pharm.D., CLP,
has been appointed as an independent director to Ariel's board of directors. 

ZILA acquires product portfolios

Friday, March 30, 2012

ZILA, Inc. a TOLMAR Company, acquires the soft tissue diode laser, Zen™ and Insight™ product portfolios from Discus Dental. 

PharmaJet Wins Innovative Technology Award

Tuesday, March 27, 2012

Jefferson County's 19th Annual Industry Awards ceremony, honoring leading businesses in Colorado's Jefferson County.   

Clovis Oncology files for $75M stock offering

Monday, March 26, 2012

Denver Business Journal 

Ventria Bioscience and EMD Millipore Announce Exclusive Agreement

Wednesday, March 21, 2012

Ventria Bioscience and EMD Millipore Announce Exclusive Global Supply and Marketing Agreement

Ventria to use ExpressTec to manufacture and supply materials for animal component-free cell culture products 

March 2012 FOCUS Newsletter

Wednesday, March 21, 2012

 

Supreme Court rejects 2 personalized medicine patents

Tuesday, March 20, 2012

The U.S. Supreme Court has thrown out two patents held by Prometheus Laboratories involving a blood test that helps doctors determine the best dosage for thiopurine for treating patients with autoimmune disease. Prometheus' method of monitoring a patient and adjusting dosage as needed is based on laws of nature and cannot be patented, the court said. The ruling could threaten existing patents and discourage future patent applications involving personalized medicine. BIO is "surprised and disappointed in the court's decision," said deputy general counsel Hans Sauer.  

CBSA Commends PhRMA and We Work For Health for Clinical Trial Report

Monday, March 19, 2012

Colorado BioScience Association Commends PhRMA and We Work For Health for Showcasing
the Critical Importance of Clinical Trials to Chronic Disease Sufferers in the State
 

DBJ-Surefire, Intio take unique approaches to tech development

Friday, March 16, 2012

Denver-area companies Surefire Medical Inc. and Intio share a lot of traits that distinguish them from typical bioscience companies.